Clinical trial NCT06083129: Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor
Official title: Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor Following a Reduced Intensity Conditioning Regimen by Fludarabine-treosulfan
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: GVHD
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2023-10-13
Enrollment: 324
Sex: ALL
Minimum age (years): 50
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative therapy in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Most of the patients requiring an allo-HSCT are above 50 years of age and are transplanted with a reduced intensity conditioning (RIC) regimen. The optimal RIC and Graft Versus Host Disease (GVHD) prophylaxis regimen allowing a good control of the disease while preventing GVHD remains to be determined for elderly patients. A phase III trial comparing the conventional RIC fludarabine-busulfan 2 days to fludarabine-treosulfan demonstrated an advantage for the flu-treosulfan arm in terms of event free survival (EFS), that should therefore be considered as the new standard of RIC regimen for AML and MDS. GVHD prevention has a crucial role in post-transplant outcomes by potentially interfering with the graft-versus-leukemia (GVL) effect and immune reconstitution. Anti-thymocyte globulins (ATG) are recommended to reduce the risk of acute and chronic GVHD in transplants performed with matched unrelated donors. However, the optimal type of ATG between the 2 approved brands (ATG-thymoglobulin and ATLG-grafalon) displaying distinct characteristics and the optimal dose of ATG are still unknown. In a retrospective study of patients transplanted mainly with RIC with matched related and unrelated donors for haematological malignancies, we observed that Anti-T lymphocyte globulin (ATLG) was associated with a reduction of grade II-IV acute GVHD in comparison to ATG without increasing the incidence of relapse.

In this phase III randomised study, we propose to compare GVHD prevention with ATG versus ATLG in AML and MDS patients above 50 years of age transplanted with a matched unrelated donor following a fludarabine-treosulfan RIC, with the hypothesis that ATLG would better control GVHD in this population of patients thus limiting the risk of morbidity and mortality of the procedure.


Eligibility criteria: Inclusion Criteria:

1. Age ≥ 50 and ≤ 70 years
2. Patient between 50 and 55 years should be unfit for a myeloblative conditioning (SORROR score ≥2)
3. AML requiring allogeneic stem cell transplantation (intermediate or high-risk AML) in complete cytologic response (CR1 or above) or MDS requiring allogeneic stem cell transplantation (IPSS≥ 1.5 or IPSS-R \> 4.5 or IPSS-R \> 3-4.5 with risk features \[rapide blast increase, life-threatening neutropenia (\<0.3 G/L) or thrombopenia (\<30G/L) or high transfusion needs (\>2/month for 6 months)\]
4. Without an HLA matched related donor
5. Having an identified matched HLA 10/10 unrelated donor
6. With usual criteria for HSCT:

   1. ECOG performans status ≤ 2
   2. No severe and uncontrolled infection
   3. Cardiac left ventricular ejection fraction ≥50%
   4. Lung DLCO \> 40%
   5. Adequate organ function: ASAT and ALAT ≤ 3N, total bilirubin ≤ 2N, creatinine clearance ≥ 50 mL/min (except if those abnormalities are linked to the hematological disease)
7. With health insurance coverage
8. Having signed a written informed consent
9. Contraception methods must be prescribed during all the duration of the research

NB: The authorized contraceptive methods are:

* For women of childbearing age and in absence of permanent sterilization: oral, intravaginal or transdermal combined hormonal contraception, oral, injectable or transdermal progestogen-only hormonal contraception, intrauterine hormonal releasing system (IUS), sexual abstinence (only if this the preferred and usual lifestyle of the participants).
* For man in absence of permanent sterilization: sexual abstinence, condoms

Exclusion Criteria:

1. Cancer in the last 5 years (except basal cell carcinoma of the skin or "in situ" carcinoma of the cervix)
2. Uncontrolled infection
3. Seropositivity for HIV or HTLV-1 or active hepatitis B or C
4. Yellow fever vaccine and all others live virus vaccines within 2 months before transplantation
5. Heart failure according to NYHA (II or more) or Left ventricular ejection fraction \< 50%.
6. Lung DLCO ≤ 40%
7. Preexisting acute hemorrhagic cystitis
8. Renal failure with creatinine clearance \< 50ml / min
9. Pregnancy (β-HCG positive) or breast-feeding
10. Patients with any debilitating medical or psychiatric illness, which would preclude the realization of the SCT or the understanding of the protocol
11. Patient under state medical aid
12. Patient under legal protection (protection of the court, or in curatorship or guardianship).
13. For Grafalon: Hypersensitivity to the active substance or to any of the excipients
14. For Thymoglobulin: Hypersensitivity to rabbit proteins or to any of the excipients
15. Participation in other interventional clinical trials
16. Any contraindication mentioned in the SmPC of all auxiliary medicinal products planned to be used in the trial: cyclosporine, mycophenolate mofetil, fludarabine, treosulfan

Primary outcomes:
measure: Incidence of grade II-IV acute Graft Versus Host Disease (GVHD) according to the Mount Sinai Acute GVHD International Consortium (MAGIC) classification
timeFrame: At day 100 post-transplantation
Secondary outcomes:
measure: Number of patients with at least 3 consecutive days with neutrophils > 0.5 G/L and platelets > 20 G/L
timeFrame: Up to 24 months
measure: T, B, NK, regulatory T cell and gammaglobulin levels in the peripheral blood
timeFrame: 1 month after transplantation
measure: T, B, NK, regulatory T cell and gammaglobulin levels in the peripheral blood
timeFrame: 100 days after transplantation
measure: T, B, NK, regulatory T cell and gammaglobulin levels in the peripheral blood
timeFrame: 6 months after transplantation
measure: T, B, NK, regulatory T cell and gammaglobulin levels in the peripheral blood
timeFrame: 12 months after transplantation
measure: T, B, NK, regulatory T cell and gammaglobulin levels in the peripheral blood
timeFrame: 24 months after transplantation
measure: Percentage of chimerism
timeFrame: 1 month after transplantation
measure: Percentage of chimerism
timeFrame: 100 days after transplantation
measure: Percentage of chimerism
timeFrame: 6 months after transplantation
measure: Percentage of chimerism
timeFrame: 12 months after transplantation
measure: Incidence of grade I acute GVHD
timeFrame: Up to 24 months
measure: Incidence of chronic GVHD
timeFrame: 12 months after transplantation
measure: Incidence of chronic GVHD
timeFrame: 24 months after transplantation
measure: Incidence of relapse
timeFrame: 12 months after transplantation
measure: Incidence of relapse
timeFrame: 24 months after transplantation
measure: Progression free survival
timeFrame: 12 months after transplantation
measure: Progression free survival
timeFrame: 24 months after transplantation
measure: Number of severe infections
timeFrame: 100 days after transplantation
measure: Number of severe infections
timeFrame: 12 months after transplantation
measure: Incidence of CytoMegaloVirus (CMV) reactivation
timeFrame: 100 days after transplantation
measure: Incidence of CytoMegaloVirus (CMV) reactivation
timeFrame: 6 months after transplantation
measure: Incidence of CytoMegaloVirus (CMV) reactivation
timeFrame: 12 months after transplantation
measure: Incidence of Ebstein Barr Virus (EBV) reactivation
timeFrame: 100 days after transplantation
measure: Incidence of Ebstein Barr Virus (EBV) reactivation
timeFrame: 6 months after transplantation
measure: Incidence of Ebstein Barr Virus (EBV) reactivation
timeFrame: 12 months after transplantation
measure: Non-relapse mortality
timeFrame: 6 months after transplantation
measure: Non-relapse mortality
timeFrame: 12 months after transplantation
measure: Non-relapse mortality
timeFrame: 24 months after transplantation
measure: Overall survival
timeFrame: 12 months after transplantation
measure: Overall survival
timeFrame: 24 months after transplantation
measure: GVHD and relapse free survival (GRFS)
timeFrame: Up to 24 months after transplantation
measure: Health-related Quality of life
timeFrame: At inclusion
measure: Health-related Quality of life
timeFrame: 100 days after transplantation
measure: Health-related Quality of life
timeFrame: 6 months after transplantation
measure: Health-related Quality of life
timeFrame: 12 months after transplantation
measure: Number of days of hospitalization for the transplant and after the hospitalization for transplantation related complications
timeFrame: Up to 12 months after transplantation
measure: Incidence and severity of veino-occlusive disease (VOD)
timeFrame: 100 days after transplantation
measure: Lymphocyte counts on standard blood counts before conditioning
timeFrame: 7 days before transplantation
measure: Number of late acute GvHD, overlap syndromes and chronic GvHD
timeFrame: from day 100 to day 120 after transplantation
Other outcomes:
Locations:
Study officials:
References: